138 related articles for article (PubMed ID: 19734419)
1. A polymorphism in NFKB1 is associated with improved effect of interferon-{alpha} maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell support.
Vangsted AJ; Klausen TW; Gimsing P; Andersen NF; Abildgaard N; Gregersen H; Vogel U
Haematologica; 2009 Sep; 94(9):1274-81. PubMed ID: 19734419
[TBL] [Abstract][Full Text] [Related]
2. NFKB1 -94ins/delATTG polymorphism is a novel prognostic marker in first line-treated multiple myeloma.
Varga G; Mikala G; Andrikovics H; Koszarska M; Balassa K; Ádám E; Kozma A; Tordai A; Masszi T
Br J Haematol; 2015 Mar; 168(5):679-88. PubMed ID: 25363231
[TBL] [Abstract][Full Text] [Related]
3. Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib.
Vangsted AJ; Klausen TW; Abildgaard N; Andersen NF; Gimsing P; Gregersen H; Nexø BA; Vogel U
Ann Hematol; 2011 Oct; 90(10):1173-81. PubMed ID: 21347685
[TBL] [Abstract][Full Text] [Related]
4. The importance of a sub-region on chromosome 19q13.3 for prognosis of multiple myeloma patients after high-dose treatment and stem cell support: a linkage disequilibrium mapping in RAI and CD3EAP.
Vangsted AJ; Klausen TW; Gimsing P; Abildgaard N; Andersen NF; Gregersen H; Nexø BA; Vogel UB
Ann Hematol; 2011 Jun; 90(6):675-84. PubMed ID: 21046104
[TBL] [Abstract][Full Text] [Related]
5. NFKB1 promoter -94 insertion/deletion ATTG polymorphism (rs28362491) is associated with severity and disease progression of rheumatoid arthritis through interleukin-6 levels modulation in Egyptian patients.
Elkhawaga SY; Gomaa MH; Elsayed MM; Ebeed AA
Clin Rheumatol; 2021 Jul; 40(7):2927-2937. PubMed ID: 33459954
[TBL] [Abstract][Full Text] [Related]
6. The polymorphism IL-1beta T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCT.
Vangsted AJ; Klausen TW; Ruminski W; Gimsing P; Andersen NF; Gang AO; Abildgaard N; Knudsen LM; Nielsen JL; Gregersen H; Vogel U
Bone Marrow Transplant; 2009 Apr; 43(7):539-45. PubMed ID: 18997828
[TBL] [Abstract][Full Text] [Related]
7. Association of NFKB1 -94ins/delATTG promoter polymorphism with susceptibility to autoimmune and inflammatory diseases: a meta-analysis.
Zou YF; Wang F; Feng XL; Tao JH; Zhu JM; Pan FM; Su H
Tissue Antigens; 2011 Jan; 77(1):9-17. PubMed ID: 21155719
[TBL] [Abstract][Full Text] [Related]
8. NFKB1 promoter polymorphism: A new predictive marker of cytomegalovirus infection after kidney transplantation.
Leone F; Gigliotti P; La Russa A; Lofaro D; Perri A; Vizza D; Lupinacci S; Toteda G; Bonofiglio M; Presta P; Talarico R; Aquino B; Bonofiglio R
Transpl Infect Dis; 2019 Feb; 21(1):e13027. PubMed ID: 30431214
[TBL] [Abstract][Full Text] [Related]
9. Functional polymorphism of the NFKB1 gene promoter is not relevant in predisposition to celiac disease.
Rueda B; Núñez C; López-Nevot MA; Paz Ruiz M; Urcelay E; De la Concha EG; Martín J
Scand J Gastroenterol; 2006 Apr; 41(4):420-3. PubMed ID: 16635909
[TBL] [Abstract][Full Text] [Related]
10. Lack of association of a functional -94ins/delATTG NFKB1 promoter polymorphism with susceptibility and clinical expression of biopsy-proven giant cell arteritis in northwest Spain.
Martin J; Perez-Armengol C; Miranda-Filloy JA; Vilchez JR; Lopez-Nevot MA; Garcia-Porrua C; Gonzalez-Gay MA
J Rheumatol; 2006 Feb; 33(2):285-8. PubMed ID: 16465659
[TBL] [Abstract][Full Text] [Related]
11. Interaction between obesity and the NFKB1 - 94ins/delATTG promoter polymorphism in relation to incident acute coronary syndrome: a follow up study in three independent cohorts.
Stegger JG; Schmidt EB; Berentzen TL; Tjønneland A; Vogel U; Rimm E; Sørensen TI; Overvad K; Jensen MK
PLoS One; 2013; 8(5):e63004. PubMed ID: 23671649
[TBL] [Abstract][Full Text] [Related]
12. The
Nowak H; Vornweg S; Rump K; Rahmel T; Unterberg M; Koos B; Schenker P; Viebahn R; Adamzik M; Bergmann L
Cells; 2021 Feb; 10(2):. PubMed ID: 33673169
[TBL] [Abstract][Full Text] [Related]
13. A functional polymorphism in the promoter region of the IL1B gene is associated with risk of multiple myeloma.
Vangsted AJ; Nielsen KR; Klausen TW; Haukaas E; Tjønneland A; Vogel U
Br J Haematol; 2012 Aug; 158(4):515-8. PubMed ID: 22540426
[TBL] [Abstract][Full Text] [Related]
14. Association and interaction of NFKB1 rs28362491 insertion/deletion ATTG polymorphism and PPP1R13L and CD3EAP related to lung cancer risk in a Chinese population.
Yin J; Wang H; Vogel U; Wang C; Hou W; Ma Y
Tumour Biol; 2016 Apr; 37(4):5467-73. PubMed ID: 26563375
[TBL] [Abstract][Full Text] [Related]
15. Association between NFKB1 -94ins/delATTG promoter polymorphism and cancer risk: a meta-analysis.
Zou YF; Yuan FL; Feng XL; Tao JH; Ding N; Pan FM; Wang F
Cancer Invest; 2011 Jan; 29(1):78-85. PubMed ID: 21166501
[TBL] [Abstract][Full Text] [Related]
16. Hydrocortisone fails to abolish NF-κB1 protein nuclear translocation in deletion allele carriers of the NFKB1 promoter polymorphism (-94ins/delATTG) and is associated with increased 30-day mortality in septic shock.
Schäfer ST; Gessner S; Scherag A; Rump K; Frey UH; Siffert W; Westendorf AM; Steinmann J; Peters J; Adamzik M
PLoS One; 2014; 9(8):e104953. PubMed ID: 25133403
[TBL] [Abstract][Full Text] [Related]
17. Association study of NFKB1 and SUMO4 polymorphisms in Chinese patients with psoriasis vulgaris.
Li H; Gao L; Shen Z; Li CY; Li K; Li M; Lv YJ; Li CX; Gao TW; Liu YF
Arch Dermatol Res; 2008 Sep; 300(8):425-33. PubMed ID: 18330586
[TBL] [Abstract][Full Text] [Related]
18. Role of the NFKB1 -94ins/delATTG promoter polymorphism in IBD and potential interactions with polymorphisms in the CARD15/NOD2, IKBL, and IL-1RN genes.
Glas J; Török HP; Tonenchi L; Müller-Myhsok B; Mussack T; Wetzke M; Klein W; Epplen JT; Griga T; Schiemann U; Lohse P; Seiderer J; Schnitzler F; Brand S; Ochsenkühn T; Folwaczny M; Folwaczny C
Inflamm Bowel Dis; 2006 Jul; 12(7):606-11. PubMed ID: 16804398
[TBL] [Abstract][Full Text] [Related]
19. Variations in Toll-like receptor and nuclear factor-kappa B genes and the risk of glioma.
Kına I; Sultuybek GK; Soydas T; Yenmis G; Biceroglu H; Dirican A; Uzan M; Ulutin T
Br J Neurosurg; 2019 Apr; 33(2):165-170. PubMed ID: 30450997
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms in the genes ERCC2, XRCC3 and CD3EAP influence treatment outcome in multiple myeloma patients undergoing autologous bone marrow transplantation.
Vangsted A; Gimsing P; Klausen TW; Nexø BA; Wallin H; Andersen P; Hokland P; Lillevang ST; Vogel U
Int J Cancer; 2007 Mar; 120(5):1036-45. PubMed ID: 17131345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
